Evidence · outcome measures
How hyperhidrosis is measured
Five instruments do most of the measuring in hyperhidrosis research and clinical practice. HDSS is the consumer-facing severity scale; HDSM-Ax-7 and ASDD are the patient-reported primary endpoints in the Qbrexza and Sofdra Phase 3 trials; Gravimetric Sweat Production is the objective sweat-rate measure; DLQI captures quality-of-life impact.
The five measures
Hyperhidrosis Disease Severity Scale (HDSS)
Type: patient reported · Scale: 1–4 · Consumer-facing
consumer self-assessment + clinical trial outcome
Hyperhidrosis Disease Severity Measure — Axillary, 7-day recall (HDSM-Ax-7)
Type: patient reported · Scale: 0–10
Sofdra (CARDIGAN-1, CARDIGAN-2) primary endpoint
Axillary Sweating Daily Diary (ASDD)
Type: patient reported · Scale: 0–10
Qbrexza (ATMOS-1, ATMOS-2) primary endpoint
Gravimetric Sweat Production (GSP)
Type: objective measure
objective sweat-rate measurement (mg over a defined interval)
Dermatology Life Quality Index (DLQI)
Type: patient reported · Scale: 0–30
quality-of-life impact in dermatology trials including hyperhidrosis